The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation

Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment

(2018) Daniela Belloni et al.   HAEMATOLOGICA

Role of Bruton’s tyrosine kinase in B cells and malignancies

(2018) Simar Pal Singh et al.   Molecular Cancer

Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment

(2018) Daniela Belloni et al.   HAEMATOLOGICA

Cellular and molecular mechanisms underlying planar cell polarity pathway contributions to cancer malignancy

(2018) Kacey VanderVorst et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment

(2017) R E Piddock et al.   Blood Cancer Journal

ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration

(2016) Sean S. Q. Ma et al.   BMC CANCER

Advances in understanding prognosis in myeloma

(2016) Dean Smith et al.   BRITISH JOURNAL OF HAEMATOLOGY

Generating Cellular Diversity and Spatial Form: Wnt Signaling and the Evolution of Multicellular Animals

(2016) Kyle M. Loh et al.   DEVELOPMENTAL CELL

Wnt Signaling in Cell Motility and Invasion: Drawing Parallels between Development and Cancer

(2016) Alanna Sedgwick et al.   Cancers

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

(2015) Jian Yu et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulation of the expression of Wnt5a promotes the proliferation of pancreatic cancer cells in vitro and in a nude mouse model

(2015) HAIJI BO et al.   Molecular Medicine Reports

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ror2 as a Therapeutic Target in Cancer

(2015) Zufan Debebe et al.   PHARMACOLOGY & THERAPEUTICS

Wnt5a promotes cancer cell invasion and proliferation by receptor-mediated endocytosis-dependent and -independent mechanisms, respectively

(2015) Kensaku Shojima et al.   Scientific Reports

Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals

(2014) Ailiang Zhang et al.   Cancer Cell International

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

(2012) Torsten Steinbrunn et al.   BRITISH JOURNAL OF HAEMATOLOGY

PI3K/Akt-dependent phosphorylation of GSK3β and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration

(2012) Jiaojing Liu et al.   CELLULAR SIGNALLING

Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape

(2012) Jan A. Burger   CURRENT OPINION IN ONCOLOGY

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells

(2012) M Bolzoni et al.   LEUKEMIA

Alternative Wnt Pathways and Receptors

(2012) R. van Amerongen   Cold Spring Harbor Perspectives in Biology

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

(2010) Karène Mahtouk et al.   BMC CANCER

Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer

(2010) Ester Lara et al.   Molecular Cancer

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma

(2009) M P O’Connell et al.   ONCOGENE

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

(2008) H. Rozemuller et al.   HAEMATOLOGICA

The Deleted in Brachydactyly B Domain of ROR2 Is Required for Receptor Activation by Recruitment of Src

(2008) Shiva Akbarzadeh et al.   PLoS One